Mast cells promote lung vascular remodelling in pulmonary hypertension

European Respiratory Journal

Volumn 37, Issue 6, 2011, Pages 1400-1410

  Hoffmann, J ^a   Yin, J ^a,f   Kukucka, M ^b   Yin, N ^a   Saarikko, I ^h   Sterner Kock, A ^c   Fujii, H ^f   Leong Poi, H ^f   Kuppe, H ^b   Schermuly, R T ^d,e   Kuebler, W M ^a,f,g  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^e MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^f ST MICHAEL'S HOSPITAL   (Canada)

^g UNIVERSITY OF TORONTO   (Canada)

^h Genolyze Ltd   (Finland)

Author keywords

Heart failure; Mast cells; Pulmonary hypertension; Vascular remodelling

Indexed keywords

KETOTIFEN; RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR PARAMETERS; CELL ACTIVATION; CONTROLLED STUDY; GENE CLUSTER; HEART DISEASE; IN VIVO STUDY; LEFT HEART DISEASE; LUNG VASCULAR REMODELLING; MAST CELL; MICROARRAY ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

ANIMALS; GENE EXPRESSION PROFILING; HISTAMINE H1 ANTAGONISTS; HYPERTENSION, PULMONARY; KETOTIFEN; LUNG; MALE; MAST CELLS; MONOCROTALINE; RATS; RATS, SPRAGUE-DAWLEY; UP-REGULATION; VENTRICULAR DYSFUNCTION, LEFT;

EID: 79957999313     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00043310     Document Type: Article

References (33)

1. Ghio S, Gavazzi A, Campana C, et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 2001; 37: 183-188. (Pubitemid 32051736)
2. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: Suppl. 1 S43-S54.
3. Lam CS, Roger VL, Rodeheffer RJ, et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a communitybased study. J Am Coll Cardiol 2009; 53: 1119-1126.
4. Delgado JF, Conde E, Sanchez V, et al. Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. Eur J Heart Fail 2005; 7: 1011-1016. (Pubitemid 41443595)
5. 2+ signaling and cytoskeletal reorganization. Circ Res 2010; 106: 1103-1116.
6. Yin N, Kaestle S, Yin J, et al. Inhaled nitric oxide versus aerosolized iloprost for the treatment of pulmonary hypertension with left heart disease. Crit Care Med 2009; 37: 980-986.
7. Kuebler WM, Hoffman J. Expression data from lungs of rats with pulmonary hypertension. www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc5GSE16624 Date last accessed: June 16, 2009. Date last updated: June 16, 2009.
8. Niwa Y, Kasugai T, Ohno K, et al. Anemia and mast cell depletion in mutant rats that are homozygous at "white spotting (Ws)" locus. Blood 1991; 78: 1936-1941.
9. Marks RM, Roche WR, Czerniecki M, et al. Mast cell granules cause proliferation of human microvascular endothelial cells. Lab Invest 1986; 55: 289-294. (Pubitemid 16006492)
10. Cho SH, Yao Z, Wang SW, et al. Regulation of activin A expression in mast cells and asthma: its effect on the proliferation of human airway smooth muscle cells. J Immunol 2003; 170: 4045-4052. (Pubitemid 36428166)
11. Ehrlich P. Beiträge zur Kenntnis der granulierten Bindegewebszellen und der eosinophilen Leukozyten. [Contributions to the knowledge of the granulated connective tissue cells and eosinophilic leukocytes.]. Arch Anat Physiol 1879; 3: 166-169.
12. Heath D, Trueman T, Sukonthamarn P. Pulmonary mast cells in mitral stenosis. Cardiovasc Res 1969; 3: 467-471.
13. Heath D, Yacoub M. Lung mast cells in plexogenic pulmonary arteriopathy. J Clin Pathol 1991; 44: 1003-1006.
14. Kay JM, Waymire JC, Grover RF. Lung mast cell hyperplasia and pulmonary histamine-forming capacity in hypoxic rats. Am J Physiol 1974; 226: 178-184.
15. Tucker A, McMurtry IF, Alexander AF, et al. Lung mast cell density and distribution in chronically hypoxic animals. J Appl Physiol 1977; 42: 174-178. (Pubitemid 8038589)
16. Maclean MR, Dempsie Y. Serotonin and pulmonary hypertension - from bench to bedside? Curr Opin Pharmacol 2009; 9: 281-286.
17. Ferreira AJ, Shenoy V, Yamazato Y, et al. Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am J Respir Crit Care Med 2009; 179: 1048-1054.
18. Miyazaki M, Takai S, Jin D, et al. Pathological roles of angiotensin II produced by mast cell chymase and the effects of chymase inhibition in animal models. Pharmacol Ther 2006; 112: 668-676. (Pubitemid 44573489)
19. Tchougounova E, Lundequist A, Fajardo I, et al. A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix metalloprotease-2. J Biol Chem 2005; 280: 9291-9296. (Pubitemid 40409621)
20. Maxova H, Novotna J, Vajner L, et al. In vitro hypoxia increases production of matrix metalloproteinases and tryptase in isolated rat lung mast cells. Physiol Res 2008; 57: 903-910.
21. Okayama Y, Ra C, Saito H. Role of mast cells in airway remodeling. Curr Opin Immunol 2007; 19: 687-693. (Pubitemid 350236804)
22. Savale L, Tu L, Rideau D, et al. Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir Res 2009; 10: 6.
23. Humbert M, Monti G, Brenot F, et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995; 151: 1628-1631.
24. Gilfillan AM, Rivera J. The tyrosine kinase network regulating mast cell activation. Immunol Rev 2009; 228: 149-169.
25. Klein M, Schermuly RT, Ellinghaus P, et al. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. Circulation 2008; 118: 2081-2090.
26. Schermuly RT, Dony E, Ghofrani HA, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005; 115: 2811-2821. (Pubitemid 41434408)
27. Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008; 26: 127-132.
28. Castillo JG, Oehling A, Gamboa PM. Mechanism of ketotifen action in hypersensitivity reactions. Its effect on cellular enzymatic activities. J Investig Allergol Clin Immunol 1991; 1: 315-323.
29. Lowe DA, Richardson BP. Effects of cyproheptadine, ketotifen and sodium nitroprusside on mechanical activity and calcium uptake in guinea pig taenia coli in vitro. Respiration 1980; 39: Suppl. 1, 44-46. (Pubitemid 10014714)
30. Davie NJ, Crossno JT, Frid MG, et al. Hypoxia-induced pulmonary artery adventitial remodeling and neovascularization: contribution of progenitor cells. Am J Physiol Lung Cell Mol Physiol 2004; 286: L668-L678. (Pubitemid 38365049)
31. Miettinen M, Lasota J. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol 2005; 13: 205-220. (Pubitemid 41209013)
32. Banasova A, Maxova H, Hampl V, et al. Prevention of mast cell degranulation by disodium cromoglycate attenuates the development of hypoxic pulmonary hypertension in rats exposed to chronic hypoxia. Respiration 2008; 76: 102-107. (Pubitemid 351914146)
33. Zhu YJ, Kradin R, Brandstetter RD, et al. Hypoxic pulmonary hypertension in the mast cell-deficient mouse. J Appl Physiol 1983; 54: 680-686. (Pubitemid 13115067)